(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32%.
Passage Bio's earnings in 2026 is -$36,112,000.On average, 5 Wall Street analysts forecast PASG's earnings for 2026 to be -$32,099,585, with the lowest PASG earnings forecast at -$30,840,778, and the highest PASG earnings forecast at -$33,043,691. On average, 4 Wall Street analysts forecast PASG's earnings for 2027 to be -$33,478,095, with the lowest PASG earnings forecast at -$32,165,229, and the highest PASG earnings forecast at -$34,462,745.
In 2028, PASG is forecast to generate -$29,112,814 in earnings, with the lowest earnings forecast at -$27,971,135 and the highest earnings forecast at -$29,969,073.